文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET/CT引导靶向穿刺在mpMRI阴性或可疑前列腺癌中的应用:FUPERMAN研究

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.
PubMed 文献 · J Nucl Med · 2026-09-02

FUPERMAN研究前瞻性纳入63例PI-RADS 2-3的mpMRI阴性或可疑男性,行[68Ga]Ga-PSMA-11 PET/CT后经会阴前列腺穿刺,比较PET引导靶向穿刺(PET-TB)与系统穿刺(SB)对临床显著前列腺癌(csPCa)的检出率,并探索SUVmax及动态全身PET参数的预测价值。PET-TB检出csPCa显著优于SB(37% vs. 21%,P=0.021),联合两者检出率升至41%,SUVmax可独立预测csPCa。

要点

  • PET-TB对csPCa检出率显著高于SB(37% vs. 21%,P=0.021)。
  • PET-TB联合SB可将csPCa检出率提高至41%。
  • SUVmax独立预测csPCa,阈值11.4时特异度达100%。

核心结论

  • PSMA PET/CT引导靶向穿刺可提高mpMRI阴性或可疑男性的csPCa检出率。
  • SUVmax和动态全身PET参数对csPCa具有额外预测价值。
  • 上述有前景的发现需在更大规模多中心试验中验证。

研究设计与样本

  • 前瞻性单中心研究,2023年3月至2025年7月纳入63例PI-RADS 2-3的mpMRI阴性或可疑男性。
  • 所有患者行[68Ga]Ga-PSMA-11 PET/CT后接受经会阴前列腺穿刺。
  • 其中11例患者接受动态全身PET检查。
  • 主要终点为csPCa检出(国际泌尿病理学会评分≥2)。
  • 比较PET-TB与SB的诊断效能,采用logistic回归评估预测因子,并对动态PET数据进行动力学建模分析。

主要发现

  • PET-TB检出csPCa显著多于SB(37% vs. 21%;P=0.021)。
  • PET-TB的敏感度为96%、特异度为49%、阳性预测值为57%、阴性预测值为95%。
  • PET-TB联合SB使csPCa检出率提高至41%。
  • SUVmax独立预测csPCa(OR=51.2;95%CI 5.6-2713.9;P=0.015),阈值11.4时特异度达100%。
  • 动态PET分析中csPCa表现为不可逆动力学,Ki/k3参数在SUV基础上改善病灶鉴别,尤其在PRIMARY评分3的可疑病灶中。

关键数值与推荐

  • csPCa定义为国际泌尿病理学会评分≥2。
  • PET-TB检出csPCa为37%,SB为21%,联合为41%。
  • PET-TB敏感度96%、特异度49%、阳性预测值57%、阴性预测值95%。
  • SUVmax预测csPCa的OR为51.2(95%CI 5.6-2713.9;P=0.015),阈值11.4对应特异度100%。

临床怎么用

  • 对mpMRI阴性或可疑(PI-RADS 2-3)且诊断不确定的男性,可考虑PSMA PET/CT引导靶向穿刺以提高csPCa检出。
  • PET-TB联合系统穿刺可进一步提高csPCa检出率至41%。
  • SUVmax阈值11.4时特异度达100%,可作为预测csPCa的参考指标。
  • 动态全身PET的Ki/k3参数有助于在SUV基础上改善病灶鉴别,尤其对PRIMARY评分3的可疑病灶。

局限性

  • 本研究为单中心前瞻性研究,样本量63例,动态全身PET仅11例。
  • 作者指出上述有前景的发现需在更大规模多中心试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) PET/CT may enhance detection of clinically significant prostate cancer (csPCa) in men with negative or equivocal multiparametric MRI (mpMRI), a setting where diagnostic uncertainty persists. This study assessed the diagnostic performance of PSMA PET/CT-guided targeted biopsy (PET-TB) versus systematic biopsy (SB) and explored the value of semiquantitative (SUVmax) and dynamic total-body PET parameters in predicting csPCa. Methods: This is a prospective, single-center study that enrolled 63 men with PI-RADS 2-3 mpMRI findings between March 2023 and July 2025. All underwent [68Ga]Ga-PSMA-11 PET/CT followed by transperineal prostate biopsy. A subset of 11 patients underwent dynamic total-body PET. The primary endpoint was detection of csPCa (International Society of Urological Pathology score of ≥2). We compared diagnostic yields of PET-TB and SB, evaluated predictors via logistic regression, and analyzed dynamic PET data using kinetic modeling. Results: PET-TB detected significantly more csPCa than did SB (37% vs. 21%; P = 0.021), achieving a sensitivity of 96%, a specificity of 49%, a positive predictive value of 57%, and a negative predictive value of 95%. Combining PET-TB with SB increased the csPCa detection rate to 41%. SUVmax independently predicted csPCa (odds ratio, 51.2; 95% CI, 5.6-2713.9; P = 0.015), with a threshold of 11.4 yielding 100% specificity. In dynamic PET analysis, csPCa showed irreversible kinetics, and Ki /k 3 parameters improved lesion discrimination beyond SUV, especially in equivocal (PRIMARY score 3) lesions. Conclusion: PSMA PET/CT-guided targeted biopsy enhances csPCa detection in men with negative or equivocal mpMRI, with added predictive value from SUVmax and dynamic PET metrics. These promising findings should be validated in larger multicenter trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Farolfi A, Sgro CMP, Brusa I, et al. PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study. J Nucl Med. 2026. PMID: 42392696. doi:10.2967/jnumed.126.272108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。